Bionomics

Bionomics ROCE

Delisted

The Return on Capital Employed (ROCE) of Bionomics (BNO.AX) as of Sep 27, 2026 is -39.13 %. In the previous year, Return on Capital Employed (ROCE) was -18.23 % — a change of 114.63% (lower).

ROCE

-39.13 %

YoY

114.63%

Last updated:

In 2026, Bionomics's return on capital employed (ROCE) was -39.13 %, a 114.63% increase from the -18.23 % ROCE in the previous year.

The Bionomics ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2015
-81.74 AUD
Jan 1, 2016
-40.28 AUD
Jan 1, 2017
-13.50 AUD
Jan 1, 2018
-122.89 AUD
Jan 1, 2019
-50.29 AUD
Jan 1, 2020
-32.32 AUD
Jan 1, 2021
-18.23 AUD
Jan 1, 2022
-39.13 AUD
The Bionomics ROCE history
YEARROCEYoY
-39.13 %+114.63%
-18.23 %-43.59%
-32.32 %-35.73%
-50.29 %-59.08%
-122.89 %+810.41%
-13.50 %-66.49%
-40.28 %-50.72%
-81.74 %+1,097.20%
-6.83 %—
Access this data via the Eulerpool API
Get Free API Key

Bionomics Stock analysis

What does Bionomics do? Bionomics Ltd is an Australian biopharmaceutical company specializing in the development of novel therapeutics for the treatment of diseases of the central nervous system and cancer. The company is headquartered in Adelaide, South Australia, and has offices and research facilities in the United States and France. Bionomics was founded in 1998 by Dr. Deborah Rathjen, an experienced biotechnology manager and scientist. The company started as a spin-off from Flinders University in Adelaide, focusing initially on the discovery and development of drug candidates based on novel peptides. In 2002, Bionomics went public, gaining access to capital to expand its research activities and adjust its business strategy. Bionomics operates an integrated pharmaceutical model, ranging from the discovery and optimization of novel therapeutic targets and drugs to clinical development and market launch of pharmaceuticals. The company develops innovative technologies, including the MultiCore platform, to develop peptide-based drugs. Bionomics has two main divisions: CNS therapy and cancer therapy. The CNS therapy division focuses on the development of drugs for the treatment of central nervous system disorders, including schizophrenia, depression, anxiety disorders, neuropathic pain, spinal cord injuries, and other disorders. Bionomics is currently conducting clinical trials to evaluate the effectiveness of its leading drug candidates BN311 and BNO69 in the treatment of depression and anxiety disorders. Bionomics' cancer therapy division focuses on the discovery and development of drug candidates for the treatment of cancer. The company has identified a number of leading preclinical drug candidates based on novel targets, showing promising results in the treatment of breast, lung, ovarian, liver cancer, and other types of cancer. Bionomics has a range of products in development or in clinical stages. The company's leading product is BN311, a drug candidate for the treatment of depression based on Bionomics' MultiCore technology. BN311 has shown efficacy in preclinical studies in the treatment of depression and anxiety disorders and is currently being tested in a phase II clinical trial. BNO69 is another drug candidate from Bionomics based on the same technology. The candidate has been developed for the treatment of anxiety disorders and shows great promise. It has proven effective in preclinical studies and has the potential to revolutionize the treatment of anxiety disorders. The company is also developing drug candidates for the treatment of cancer, including BNC101, BNC105, BNC211, and BNC375. All of these drug candidates are based on novel targets and have shown promising results in preclinical studies. BNC375, a cancer immunotherapy, shows particularly promising results, and the company plans to conduct a phase I clinical trial to evaluate the efficacy of the drug in treating patients with advanced cancer. Overall, Bionomics Ltd is an emerging biopharmaceutical company specializing in the development of new and promising therapeutics for the treatment of diseases of the central nervous system and cancer. Bionomics has developed an integrated pharmaceutical model that supports innovation from discovery to commercialization and has a promising pipeline of drug candidates for the next generation of medications. Bionomics is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Bionomics's Return on Capital Employed (ROCE)

Bionomics's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Bionomics's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Bionomics's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Bionomics’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Bionomics stock

Return on Capital Employed (ROCE) of Bionomics is -39.13 % in 2026.

Return on Capital Employed (ROCE) of Bionomics changed from -18.23 % to -39.13 %, representing a 114.63% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Bionomics since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Bionomics with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API
Get Free API Key

Profitability — Bionomics

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Bionomics